Silo Pharma Inc (SILO) - Total Liabilities
Based on the latest financial reports, Silo Pharma Inc (SILO) has total liabilities worth $1.34 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SILO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Silo Pharma Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Silo Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See Silo Pharma Inc (SILO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Silo Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Silo Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Helios Energy Ltd
AU:HE8
|
Australia | AU$1.91 Million |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
USA | $4.92 Million |
|
Mha Ltd
LSE:MHA
|
UK | GBX116.19 Million |
|
Novakand Pharma AB (publ)
ST:LARK
|
USA | Skr1.24 Million |
|
XTL Biopharmaceuticals Ltd
TA:XTLB
|
Israel | ILA3.12 Million |
|
KST Beteiligungs AG
F:KSW
|
Germany | €3.01 Million |
|
Terrain Minerals Ltd
AU:TMX
|
Australia | AU$566.54K |
|
Big Tree Cloud Holdings Limited Ordinary Shares
NASDAQ:DSY
|
USA | $7.69 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Silo Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SILO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Silo Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Silo Pharma Inc (2010–2025)
The table below shows the annual total liabilities of Silo Pharma Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.30 Million | -45.34% |
| 2024-12-31 | $2.38 Million | +51.51% |
| 2023-12-31 | $1.57 Million | +20.52% |
| 2022-12-31 | $1.30 Million | -8.81% |
| 2021-12-31 | $1.43 Million | +878.24% |
| 2020-12-31 | $145.97K | -71.75% |
| 2019-12-31 | $516.74K | +15.35% |
| 2018-12-31 | $447.98K | +2.20% |
| 2017-12-31 | $438.34K | -3.26% |
| 2016-12-31 | $453.10K | -7.67% |
| 2015-12-31 | $490.76K | +21.91% |
| 2014-12-31 | $402.56K | -3.86% |
| 2013-12-31 | $418.72K | +909.61% |
| 2012-12-31 | $41.47K | +1084.94% |
| 2011-12-31 | $3.50K | -107.37% |
| 2010-12-31 | $-47.48K | -- |
About Silo Pharma Inc
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's … Read more